Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORUVAIL vs DAYPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute painful shoulder (bursitis/tendinitis),Acute gouty arthritis,Juvenile idiopathic arthritis (off-label),Dysmenorrhea (off-label)
Osteoarthritis,Rheumatoid arthritis
100 to 200 mg orally twice daily
600 mg orally once daily; max 1200 mg/day
5-9 hours (terminal elimination half-life); in elderly or renal impairment, may extend up to 20 hours; clinical context: dosing adjustments recommended in renal impairment.
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
Primarily hepatic via CYP2C9; undergoes extensive first-pass metabolism. Major metabolites include hydroxylated and carboxylated derivatives.
Primarily hepatic via CYP2C9; undergoes glucuronidation.
Primarily renal excretion of metabolites (60-80%) with less than 1% unchanged drug; biliary/fecal excretion accounts for 20-40%.
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
99% bound primarily to albumin.
>99% bound primarily to albumin.
0.1-0.2 L/kg; indicates low tissue distribution consistent with extensive protein binding.
0.15-0.2 L/kg; indicates limited extravascular distribution mainly in plasma and extracellular fluid.
Oral: 80-100% (immediate-release); topical: approximately 5% systemic absorption.
Oral: approximately 80-90%.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: contraindicated
Cr Cl 30-59 m L/min: 600 mg once daily; Cr Cl <30 m L/min: 400 mg once daily; hemodialysis: 400 mg once daily after dialysis
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated
Child-Pugh Class A: no adjustment; Class B: 400 mg once daily; Class C: avoid use
Not recommended for use in pediatric patients
Not approved for pediatric use
Initiate at lowest effective dose (100 mg/day); monitor renal function and gastrointestinal bleeding risk
Initiate at 400 mg once daily; max 600 mg once daily; monitor renal function
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Oruvail is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. DAYPRO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; use with caution in patients with asthma, pre-existing renal impairment, or hepatic impairment.
Cardiovascular risk, gastrointestinal bleeding and ulceration, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity (anemia), hepatic effects, asthma exacerbation, fluid retention, and use in pregnancy (avoid in late pregnancy).
Hypersensitivity to ketoprofen or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery; advanced renal disease; active GI bleeding or ulceration.
Aspirin allergy, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of CABG surgery, advanced renal disease, and pregnancy (third trimester).
Take with food or milk to minimize gastrointestinal irritation. Avoid alcohol as it increases risk of GI bleeding. No significant food-drug interactions; however, high-fat meals may delay absorption but does not affect overall bioavailability.
No significant food interactions. However, taking with food or antacids can reduce GI irritation. Avoid alcohol to minimize risk of gastric mucosal injury.
First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis (OR 1.21-3.08). Second trimester: Caution; NSAIDs may cause oligohydramnios. Third trimester: Contraindicated; risk of premature ductus arteriosus closure and persistent pulmonary hypertension.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac defects. Second trimester: Use only if clearly needed; possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension.
Minimal excretion in breast milk (M/P ratio not reported). Use with caution; may cause adverse effects in neonates. Consider alternative analgesics.
Oxaprozin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Due to potential adverse effects on infant renal function and platelet function, caution is advised. Avoid long-term use; short-term use with infant monitoring recommended.
No dose adjustment recommended but avoid in 3rd trimester. Use lowest effective dose for shortest duration in 1st and 2nd trimesters.
No specific dose adjustments established; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose titration based on clinical response. Use lowest effective dose for shortest duration. Avoid in third trimester.
Oruvail (ketoprofen extended-release) is an NSAID with analgesic, anti-inflammatory, and antipyretic effects. Due to its extended-release formulation, it should not be crushed or chewed. Use with caution in patients with renal impairment, history of GI bleeding, or cardiovascular disease. Monitor renal function and blood pressure periodically. It inhibits platelet aggregation similarly to aspirin but is reversible. May mask signs of infection.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~50-60 hours) allowing once-daily dosing. Use with caution in elderly or renal impairment due to reduced clearance. Monitor renal function, hepatic enzymes, and signs of GI bleeding. Avoid use with other NSAIDs or aspirin. May increase lithium, methotrexate, and warfarin levels.
Take exactly as prescribed; do not crush or chew the capsules.,Take with food or milk to reduce stomach upset.,Avoid alcohol and other NSAIDs (including over-the-counter ibuprofen or naproxen).,Report any signs of GI bleeding (black/tarry stools, vomiting blood), unexplained weight gain, edema, or worsening kidney function (decreased urination).,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Do not use if you have a history of asthma, hives, or allergic reaction to aspirin or NSAIDs.,Inform all healthcare providers that you are taking this medication, especially before surgery.
Take with food or milk to reduce stomach upset.,Swallow tablets whole; do not crush or chew.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, unusual bruising), weight gain, or edema.,Do not take with other NSAIDs or over-the-counter pain relievers without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORUVAIL vs DAYPRO, answered by our medical review team.
ORUVAIL is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever.. DAYPRO is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORUVAIL and DAYPRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORUVAIL is: 100 to 200 mg orally twice daily. The standard adult dose of DAYPRO is: 600 mg orally once daily; max 1200 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORUVAIL and DAYPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORUVAIL is classified as Category C. First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis (OR 1.21-3.08). Second trimester: Caution; NSAIDs may cause oligohydramnios. Third trime. DAYPRO is classified as Category C. Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.